Skip to main content

Advertisement

SpringerLink
Log in

LncRNA ABHD11-AS1 promotes tumor progression in papillary thyroid carcinoma by regulating EPS15L1/EGFR signaling pathway

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Objectives

lncRNA ABHD11 antisense RNA 1 (ABHD11-AS1) acts as an oncogene involved in papillary thyroid carcinoma (PTC) occurrence and progression. ABHD11-AS1 exerts biologic functions by some miRNAs and proteins to regulate multiple targets. Identification of novel mechanism of ABHD11‐AS1 could be helpful in therapeutic targeting for PTC treatment.

Methods

Differentially expressed lncRNAs were selected from TCGA database. qRT‐PCR analysis was applied to examine the expression of ABHD11‐AS1 in PTC cell lines and tissues. The relationship of ABHD11-AS1 expression and clinicopathological features was analyzed by Kaplan–Meier analysis.

Two PTC cell lines (TPC-1 and KTC-1) were transfected with pcDNA 3.1, pcDNA3.1-ABHD11-AS1, si-NC and si-ABHD11-AS1, respectively, to verify the ABHD11-AS1 oncogene-regulating capacity to promote tumor progression. The cell metastasis and proliferation had been evaluated both in vitro and in vivo.

Results

High expression of ABHD11‐AS1 was found in PTC tissues (P < 0.01), which was significantly correlated with lymph node metastasis (P < 0.05). ABHD11-AS1 overexpression noticeably promoted cell proliferation, migration, and invasion capabilities, which were obviously decreased upon ABHD11-AS1 knockdown. ABHD11-AS1 positively regulated EGFR/EPS15L1 pathway, as EGFR, EPS15L1, STAT3, and p-STAT3 were activated.

Conclusion

ABHD11‐AS1 promotes tumor progression in PTC by regulating EPS15L1/EGFR pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability statement

The data used to support the findings of this study are included within the article.

References

  1. Xie SH, et al. Time trends and age-period-cohort analyses on incidence rates of thyroid cancer in Shanghai and Hong Kong. BMC Cancer. 2014;14:975.

    Article  Google Scholar 

  2. Du L, et al. Incidence and mortality of thyroid cancer in China, 2008–2012. Chin J Cancer Res. 2019;31(1):144–51.

    Article  Google Scholar 

  3. Agrawal N, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676.

    Article  Google Scholar 

  4. You X, et al. Molecular characterization of papillary thyroid carcinoma: a potential three-lncRNA prognostic signature. Cancer Manag Res. 2018;10:4297–310.

    Article  CAS  Google Scholar 

  5. Shen CT, et al. Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease. Endocrine. 2019;64(3):622–31.

    Article  CAS  Google Scholar 

  6. Lundgren CI, et al. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106(3):524–31.

    Article  Google Scholar 

  7. Lu H, et al. Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma. Diagn Pathol. 2020;15(1):16.

    Article  CAS  Google Scholar 

  8. Yamashita H, et al. Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer. 1999;86(5):842–9.

    Article  CAS  Google Scholar 

  9. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298–307.

    Article  CAS  Google Scholar 

  10. Dolcino M, et al. Long non-coding RNAs play a role in the pathogenesis of psoriatic arthritis by regulating microRNAs and genes involved in inflammation and metabolic syndrome. Front Immunol. 2018;9:1533.

    Article  Google Scholar 

  11. Zhuang X, et al. Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis. Cell Death Dis. 2019;10(8):620.

    Article  Google Scholar 

  12. He D, et al. Long noncoding RNA ABHD11-AS1 promote cells proliferation and invasion of colorectal cancer via regulating the miR-1254-WNT11 pathway. J Cell Physiol. 2019;234(7):12070–9.

    Article  CAS  Google Scholar 

  13. Liu Y, et al. LncRNA ABHD11-AS1 promotes the development of endometrial carcinoma by targeting cyclin D1. J Cell Mol Med. 2018;22(8):3955–64.

    Article  CAS  Google Scholar 

  14. Wu DD, et al. Role of the lncRNA ABHD11-AS(1) in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC. Mol Cancer. 2017;16(1):138.

    Article  Google Scholar 

  15. Liu Y, et al. Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis. J Cancer. 2019;10(16):3746–56.

    Article  CAS  Google Scholar 

  16. Chen M, et al. Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer. Oncotarget. 2017;8(17):28176–86.

    Article  Google Scholar 

  17. Lin X, et al. Increased expression of long noncoding RNA ABHD11-AS1 in gastric cancer and its clinical significance. Med Oncol. 2014;31(7):42.

    Article  Google Scholar 

  18. Wen J, et al. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301–3p/STAT3 axis and PI3K/AKT signalling pathway. Cell Prolif. 2019;52(2):e12569.

    Article  Google Scholar 

  19. Tripathi V, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–38.

    Article  CAS  Google Scholar 

  20. Jin M, et al. Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas. Cancers (Basel). 2021;13(4):892.

    Article  CAS  Google Scholar 

  21. Bertoni APS, et al. The gene expression of GPER1 is low in fresh samples of papillary thyroid carcinoma (PTC), and in silico analysis. Mol Cell Endocrinol. 2021;535:111397.

    Article  CAS  Google Scholar 

  22. Huarte M, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142(3):409–19.

    Article  CAS  Google Scholar 

  23. Yap KL, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38(5):662–74.

    Article  CAS  Google Scholar 

  24. Tseng YY, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014;512(7512):82–6.

    Article  CAS  Google Scholar 

  25. Chen C, et al. Long noncoding RNA CNALPTC1 promotes cell proliferation and migration of papillary thyroid cancer via sponging miR-30 family. Am J Cancer Res. 2018;8(1):192–206.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Gou Q, et al. Long noncoding RNA AB074169 inhibits cell proliferation via modulation of KHSRP-mediated CDKN1a expression in papillary thyroid carcinoma. Can Res. 2018;78(15):4163–74.

    Article  CAS  Google Scholar 

  27. Sun W, et al. NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer. Cell Death Dis. 2018;9(3):380.

    Article  CAS  Google Scholar 

  28. Wu S, et al. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo. Clin Transl Oncol. 2021;23(8):1549–60.

    Article  CAS  Google Scholar 

  29. Zheng Q, et al. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 2021;11(2):824–40.

    Article  CAS  Google Scholar 

  30. Umair M, et al. First direct evidence of involvement of a homozygous loss-of-function variant in the EPS15L1 gene underlying split-hand/split-foot malformation. Clin Genet. 2018;93(3):699–702.

    Article  CAS  Google Scholar 

  31. Guo M, et al. The landscape of long noncoding RNA-involved and tumor-specific fusions across various cancers. Nucleic Acids Res. 2020;48(22):12618–31.

    Article  CAS  Google Scholar 

  32. Liang J, et al. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br J Cancer. 2021;125(3):390–401.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The work was supported by Department of Science and Technology of Zhejiang Province (LGF20H160029 and LGD20H160004).

Author information

Authors and Affiliations

  1. Department of Pathology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, 200072, China

    H. Lu & Q. Wei

  2. Department of Pathology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, 318000, China

    H. Lu, Y. Chen & L. Fan

  3. Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, 318000, People’s Republic of China

    C. Zhu, Y. Ruan & Q. Chen

Authors
  1. H. Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Ruan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Q. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Q. Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HL: Study design, formal analysis, writing—original draft, writing—review and editing; CZ: methodology, formal analysis, writing—original draft; YC: methodology, formal analysis, visualization; YR: methodology and visualization; LF: formal analysis; QC: conceptualization, study design, supervision, writing—review and editing; QW: conceptualization, formal analysis, writing—review and editing.

Corresponding authors

Correspondence to Q. Chen or Q. Wei.

Ethics declarations

Conflict of interest

No conflict of interest exits in the submission of this manuscript, and the manuscript was approved by all authors for publication.

Ethical approval

All procedures performed in studies involving human participants were in accordance with ethical standards of the institutional and/ or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.This study was approved by the Ethics Committee of Taizhou Central Hospital (2019-057).

Informed consent

Informed consent was obtained from the patient included in the article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, H., Zhu, C., Chen, Y. et al. LncRNA ABHD11-AS1 promotes tumor progression in papillary thyroid carcinoma by regulating EPS15L1/EGFR signaling pathway. Clin Transl Oncol 24, 1124–1133 (2022). https://doi.org/10.1007/s12094-021-02753-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-021-02753-z

Keywords

Search

Navigation